Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

494 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Adipose Triglyceride Lipase Is a Therapeutic Target in Advanced Prostate Cancer That Promotes Metabolic Plasticity.
Awad D, Cao PHA, Pulliam TL, Spradlin M, Subramani E, Tellman TV, Ribeiro CF, Muzzioli R, Jewell BE, Pakula H, Ackroyd JJ, Murray MM, Han JJ, Leng M, Jain A, Piyarathna B, Liu J, Song X, Zhang J, Klekers AR, Drake JM, Ittmann MM, Coarfa C, Piwnica-Worms D, Farach-Carson MC, Loda M, Eberlin LS, Frigo DE. Awad D, et al. Among authors: loda m. Cancer Res. 2024 Mar 4;84(5):703-724. doi: 10.1158/0008-5472.CAN-23-0555. Cancer Res. 2024. PMID: 38038968
Androgen-dependent regulation of Her-2/neu in prostate cancer cells.
Berger R, Lin DI, Nieto M, Sicinska E, Garraway LA, Adams H, Signoretti S, Hahn WC, Loda M. Berger R, et al. Among authors: loda m. Cancer Res. 2006 Jun 1;66(11):5723-8. doi: 10.1158/0008-5472.CAN-05-3928. Cancer Res. 2006. PMID: 16740710
Animal models of human prostate cancer: the consensus report of the New York meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee.
Ittmann M, Huang J, Radaelli E, Martin P, Signoretti S, Sullivan R, Simons BW, Ward JM, Robinson BD, Chu GC, Loda M, Thomas G, Borowsky A, Cardiff RD. Ittmann M, et al. Among authors: loda m. Cancer Res. 2013 May 1;73(9):2718-36. doi: 10.1158/0008-5472.CAN-12-4213. Epub 2013 Apr 22. Cancer Res. 2013. PMID: 23610450 Free PMC article.
Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors.
Chen EJ, Sowalsky AG, Gao S, Cai C, Voznesensky O, Schaefer R, Loda M, True LD, Ye H, Troncoso P, Lis RL, Kantoff PW, Montgomery RB, Nelson PS, Bubley GJ, Balk SP, Taplin ME. Chen EJ, et al. Among authors: loda m. Clin Cancer Res. 2015 Mar 15;21(6):1273-80. doi: 10.1158/1078-0432.CCR-14-1220. Epub 2014 Oct 15. Clin Cancer Res. 2015. PMID: 25320358 Free PMC article.
AKT1 and MYC induce distinctive metabolic fingerprints in human prostate cancer.
Priolo C, Pyne S, Rose J, Regan ER, Zadra G, Photopoulos C, Cacciatore S, Schultz D, Scaglia N, McDunn J, De Marzo AM, Loda M. Priolo C, et al. Among authors: loda m. Cancer Res. 2014 Dec 15;74(24):7198-204. doi: 10.1158/0008-5472.CAN-14-1490. Epub 2014 Oct 16. Cancer Res. 2014. PMID: 25322691 Free PMC article.
The Role of Lineage Plasticity in Prostate Cancer Therapy Resistance.
Beltran H, Hruszkewycz A, Scher HI, Hildesheim J, Isaacs J, Yu EY, Kelly K, Lin D, Dicker A, Arnold J, Hecht T, Wicha M, Sears R, Rowley D, White R, Gulley JL, Lee J, Diaz Meco M, Small EJ, Shen M, Knudsen K, Goodrich DW, Lotan T, Zoubeidi A, Sawyers CL, Rudin CM, Loda M, Thompson T, Rubin MA, Tawab-Amiri A, Dahut W, Nelson PS. Beltran H, et al. Among authors: loda m. Clin Cancer Res. 2019 Dec 1;25(23):6916-6924. doi: 10.1158/1078-0432.CCR-19-1423. Epub 2019 Jul 30. Clin Cancer Res. 2019. PMID: 31363002 Free PMC article.
ELOVL5 Is a Critical and Targetable Fatty Acid Elongase in Prostate Cancer.
Centenera MM, Scott JS, Machiels J, Nassar ZD, Miller DC, Zinonos I, Dehairs J, Burvenich IJG, Zadra G, Chetta PM, Bango C, Evergren E, Ryan NK, Gillis JL, Mah CY, Tieu T, Hanson AR, Carelli R, Bloch K, Panagopoulos V, Waelkens E, Derua R, Williams ED, Evdokiou A, Cifuentes-Rius A, Voelcker NH, Mills IG, Tilley WD, Scott AM, Loda M, Selth LA, Swinnen JV, Butler LM. Centenera MM, et al. Among authors: loda m. Cancer Res. 2021 Apr 1;81(7):1704-1718. doi: 10.1158/0008-5472.CAN-20-2511. Epub 2021 Feb 5. Cancer Res. 2021. PMID: 33547161
Temporal evolution of cellular heterogeneity during the progression to advanced AR-negative prostate cancer.
Brady NJ, Bagadion AM, Singh R, Conteduca V, Van Emmenis L, Arceci E, Pakula H, Carelli R, Khani F, Bakht M, Sigouros M, Bareja R, Sboner A, Elemento O, Tagawa S, Nanus DM, Loda M, Beltran H, Robinson B, Rickman DS. Brady NJ, et al. Among authors: loda m. Nat Commun. 2021 Jun 7;12(1):3372. doi: 10.1038/s41467-021-23780-y. Nat Commun. 2021. PMID: 34099734 Free PMC article.
Blocking PI3K p110β Attenuates Development of PTEN-Deficient Castration-Resistant Prostate Cancer.
Gao X, Wang Y, Ribeiro CF, Manokaran C, Chang H, Von T, Rodrigues S, Cizmecioglu O, Jia S, Korpal M, Korn JM, Wang Z, Schmit F, Jiang L, Pagliarini R, Yang Y, Sethi I, Signoretti S, Yuan GC, Loda M, Zhao JJ, Roberts TM. Gao X, et al. Among authors: loda m. Mol Cancer Res. 2022 May 4;20(5):673-685. doi: 10.1158/1541-7786.MCR-21-0322. Mol Cancer Res. 2022. PMID: 35105671 Free PMC article.
494 results